NASDAQ:CGNT - Vision Sciences Stock Price, Price Target & More

$3.85 0.00 (0.00 %)
(As of 04/22/2018 09:58 AM ET)
Previous Close$3.85
Today's Range$3.82 - $3.85
52-Week Range$1.55 - $3.92
Volume148,624 shs
Average Volume189,940 shs
Market Capitalization$234.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.58

About Vision Sciences (NASDAQ:CGNT)

Vision Sciences logoCogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.

Receive CGNT News and Ratings via Email

Sign-up to receive the latest news and ratings for CGNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGNT
CUSIPN/A
Phone952-426-6140

Debt

Debt-to-Equity RatioN/A
Current Ratio4.66%
Quick Ratio3.90%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$56.32 million
Price / Sales4.16
Cash Flow$0.0392 per share
Price / Cash98.23
Book Value$1.05 per share
Price / Book3.67

Profitability

EPS (Most Recent Fiscal Year)($0.01)
Net Income$-880,000.00
Net Margins-1.57%
Return on Equity-1.39%
Return on Assets-1.21%

Miscellaneous

Employees208
Outstanding Shares60,910,000

How to Become a New Pot Stock Millionaire

Vision Sciences (NASDAQ:CGNT) Frequently Asked Questions

What is Vision Sciences' stock symbol?

Vision Sciences trades on the NASDAQ under the ticker symbol "CGNT."

How were Vision Sciences' earnings last quarter?

Vision Sciences Inc. (NASDAQ:CGNT) issued its quarterly earnings data on Tuesday, November, 3rd. The medical device company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The medical device company earned $11.80 million during the quarter, compared to the consensus estimate of $11.45 million. Vision Sciences had a negative net margin of 1.57% and a negative return on equity of 1.39%. View Vision Sciences' Earnings History.

When is Vision Sciences' next earnings date?

Vision Sciences is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Vision Sciences.

What price target have analysts set for CGNT?

3 brokers have issued 1-year price objectives for Vision Sciences' stock. Their forecasts range from $4.00 to $5.00. On average, they expect Vision Sciences' share price to reach $4.5833 in the next year. View Analyst Ratings for Vision Sciences.

Who are some of Vision Sciences' key competitors?

Who are Vision Sciences' key executives?

Vision Sciences' management team includes the folowing people:
  • Mr. Darin Hammers, Chief Exec. Officer, Pres & Director (Age 53)
  • Mr. Brett A. Reynolds, CFO, Sr. VP & Corp. Sec. (Age 49)
  • Mr. Chris Arnold, VP of Global Sales (Age 50)
  • Mr. Larry Heinemann, VP of Corp. Devel. (Age 66)
  • Mr. Ash Keswani, Sr. VP of Marketing & Bus. Devel.

Has Vision Sciences been receiving favorable news coverage?

News coverage about CGNT stock has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vision Sciences earned a news impact score of 0.20 on Accern's scale. They also assigned media headlines about the medical device company an impact score of 45.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Vision Sciences' major shareholders?

Vision Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include CAMDEN MERGER SUB, INC. (59.40%). Company insiders that own Vision Sciences stock include Kenneth A Samet and Lewis C Pell. View Institutional Ownership Trends for Vision Sciences.

How do I buy shares of Vision Sciences?

Shares of CGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vision Sciences' stock price today?

One share of CGNT stock can currently be purchased for approximately $3.85.

How big of a company is Vision Sciences?

Vision Sciences has a market capitalization of $234.49 million and generates $56.32 million in revenue each year. The medical device company earns $-880,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Vision Sciences employs 208 workers across the globe.

How can I contact Vision Sciences?

Vision Sciences' mailing address is 5420 FELTL ROAD, MINNETONKA MN, 55343. The medical device company can be reached via phone at 952-426-6140 or via email at [email protected]


MarketBeat Community Rating for Vision Sciences (CGNT)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Vision Sciences and other stocks. Vote "Outperform" if you believe CGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vision Sciences (NASDAQ:CGNT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Vision Sciences in the last 12 months. Their average twelve-month price target is $4.5833, suggesting that the stock has a possible upside of 19.05%. The high price target for CGNT is $5.00 and the low price target for CGNT is $4.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.332.333.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.5833$4.5833$4.5833$5.00
Price Target Upside: 19.05% upside19.67% upside60.26% upside73.61% upside

Vision Sciences (NASDAQ:CGNT) Consensus Price Target History

Price Target History for Vision Sciences (NASDAQ:CGNT)

Vision Sciences (NASDAQ:CGNT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2018Roth CapitalDowngradeBuy -> Hold$4.00LowView Rating Details
3/13/2018AegisDowngradeBuy -> Hold$4.75LowView Rating Details
10/6/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$5.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Vision Sciences (NASDAQ:CGNT) Earnings History and Estimates Chart

Earnings by Quarter for Vision Sciences (NASDAQ:CGNT)

Vision Sciences (NASDAQ:CGNT) Earnings Estimates

Current Year EPS Consensus Estimate: $0.01 EPS
Next Year EPS Consensus Estimate: $0.01 EPS

Vision Sciences (NASDAQ CGNT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018N/AView Earnings Details
8/1/2017Q2 2017($0.01)$0.0070$13.90 million$14.06 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.01)($0.02)$13.14 million$12.95 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.14)$13.81 million$13.23 millionViewListenView Earnings Details
8/2/2016Q2 2016($0.03)($0.04)$12.21 million$13.01 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.03)($0.04)$14.41 million$12.21 millionViewN/AView Earnings Details
3/3/2016Q4 2015($0.07)($0.01)$12.97 million$13.64 millionViewN/AView Earnings Details
11/3/2015Q216($0.07)($0.06)$11.45 million$11.80 millionViewN/AView Earnings Details
8/10/2015Q116($0.10)($0.07)$11.34 million$11.20 millionViewListenView Earnings Details
5/14/2015Q415($0.06)($0.15)$49.10 million$7.00 millionViewListenView Earnings Details
2/4/2015Q4 2014($0.15)$4.92 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.15)$4.11 billionViewN/AView Earnings Details
8/4/2014Q2 2014($0.20)$3.75 millionViewN/AView Earnings Details
4/28/2014Q1 2014($0.20)$4.98 millionViewN/AView Earnings Details
2/3/2014Q3 14($0.03)$4.00 million$4.50 millionViewN/AView Earnings Details
11/11/2013Q3 2013($0.15)$3.97 millionViewN/AView Earnings Details
8/12/2013Q1 2014($0.05)$34.00 million$3.70 millionViewN/AView Earnings Details
4/29/2013Q1 2013($0.20)$4.43 million$4.20 millionViewN/AView Earnings Details
1/28/2013Q4 2012($0.30)($0.15)ViewN/AView Earnings Details
11/5/2012Q213($0.06)($0.07)$3.85 million$3.70 millionViewN/AView Earnings Details
7/26/2012Q2 2012($0.30)($0.30)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.30)($0.35)ViewN/AView Earnings Details
1/31/2012Q4 2011($0.25)($0.27)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.34)ViewN/AView Earnings Details
8/10/2011Q2 2011($0.30)ViewN/AView Earnings Details
6/2/2011Q1 2011($0.45)ViewN/AView Earnings Details
2/9/2011Q4 2010($0.35)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.41)ViewN/AView Earnings Details
8/11/2010Q2 2010($0.35)ViewN/AView Earnings Details
6/2/2010Q1 2010($0.50)ViewN/AView Earnings Details
2/11/2010Q4 2009($0.44)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.45)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.35)ViewN/AView Earnings Details
2/13/2009Q4 2008($0.42)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.35)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.02)ViewN/AView Earnings Details
6/30/2008Q1 2008($0.60)ViewN/AView Earnings Details
2/20/2008Q4 2007($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vision Sciences (NASDAQ:CGNT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vision Sciences (NASDAQ CGNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 62.70%
Institutional Ownership Percentage: 14.52%
Insider Trading History for Vision Sciences (NASDAQ:CGNT)
Institutional Ownership by Quarter for Vision Sciences (NASDAQ:CGNT)

Vision Sciences (NASDAQ CGNT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2016Kenneth A SametDirectorBuy25,000$2.47$61,750.00125,000View SEC Filing  
6/10/2016Lewis C PellDirectorBuy13,291$0.95$12,626.452,363,300View SEC Filing  
6/1/2016Lewis C PellDirectorBuy894$0.75$670.502,350,009View SEC Filing  
5/31/2016Lewis C PellDirectorBuy500,000$0.79$395,000.001,999,115View SEC Filing  
5/21/2015Kevin H RocheDirectorBuy10,000$1.68$16,800.00View SEC Filing  
5/19/2015Kevin H RocheDirectorBuy10,000$1.60$16,000.00View SEC Filing  
2/20/2015Lewis C PellDirectorBuy20,000$0.51$10,200.00View SEC Filing  
2/19/2015Lewis C PellDirectorBuy10,000$0.48$4,800.00View SEC Filing  
2/18/2015Lewis C PellDirectorBuy30,000$0.45$13,500.00View SEC Filing  
2/13/2015Lewis C PellDirectorBuy20,000$0.47$9,400.00View SEC Filing  
2/11/2015Lewis C PellDirectorBuy35,000$0.46$16,100.00View SEC Filing  
12/23/2014Lewis C PellDirectorBuy80,000$0.85$68,000.00View SEC Filing  
12/22/2014Lewis C PellDirectorBuy40,000$0.86$34,400.00View SEC Filing  
9/23/2014Lewis C PellDirectorBuy5,000$0.99$4,950.00View SEC Filing  
9/19/2014Lewis C PellDirectorBuy3,900$1.00$3,900.00View SEC Filing  
9/17/2014Lewis C PellDirectorBuy5,000$1.02$5,100.00View SEC Filing  
9/16/2014Lewis C PellDirectorBuy5,000$1.07$5,350.00View SEC Filing  
9/12/2014Lewis C PellDirectorBuy23,300$1.04$24,232.00View SEC Filing  
9/8/2014Lewis C PellDirectorBuy30,000$1.04$31,200.00View SEC Filing  
9/3/2014Lewis C PellDirectorBuy30,000$0.98$29,400.00View SEC Filing  
8/27/2014Lewis C PellDirectorBuy10,000$0.92$9,200.00View SEC Filing  
8/26/2014Lewis C PellDirectorBuy30,000$0.93$27,900.00View SEC Filing  
8/19/2014Lewis C PellDirectorBuy22,900$0.98$22,442.00View SEC Filing  
8/13/2014Lewis C PellDirectorBuy43,420$0.91$39,512.20View SEC Filing  
8/8/2014Lewis C PellDirectorBuy27,500$0.95$26,125.00View SEC Filing  
6/6/2014Lewis C PellDirectorBuy10,000$1.13$11,300.00View SEC Filing  
5/21/2014Lewis C PellDirectorBuy5,000$1.09$5,450.00View SEC Filing  
5/16/2014Lewis C PellDirectorBuy14,197$1.02$14,480.94View SEC Filing  
11/18/2013Lewis C PellDirectorBuy6,296$0.91$5,729.36View SEC Filing  
11/15/2013Lewis C PellDirectorBuy20,000$0.90$18,000.00View SEC Filing  
9/18/2013Lewis C PellDirectorBuy16,000$0.91$14,560.00View SEC Filing  
9/13/2013Lewis C PellDirectorBuy5,000$0.92$4,600.00View SEC Filing  
9/10/2013Lewis C PellDirectorBuy5,000$0.92$4,600.00View SEC Filing  
9/9/2013Lewis C PellDirectorBuy4,564$0.95$4,335.80View SEC Filing  
9/6/2013Lewis C PellDirectorBuy5,000$0.97$4,850.00View SEC Filing  
9/3/2013Lewis C PellDirectorBuy11,432$0.97$11,089.04View SEC Filing  
8/29/2013Lewis C PellDirectorBuy1,100$0.98$1,078.00View SEC Filing  
8/27/2013Lewis C PellDirectorBuy11,596$0.97$11,248.12View SEC Filing  
8/26/2013Lewis C PellDirectorBuy14,965$0.97$14,516.05View SEC Filing  
8/19/2013Lewis C PellDirectorBuy25,025$0.94$23,523.50View SEC Filing  
8/15/2013Lewis C PellDirectorBuy15,000$0.92$13,800.00View SEC Filing  
6/28/2013Lewis C PellDirectorBuy28,400$1.00$28,400.00View SEC Filing  
6/27/2013Lewis C PellDirectorBuy45,048$0.99$44,597.52View SEC Filing  
3/15/2013Lewis C PellDirectorBuy30,000$1.14$34,200.00View SEC Filing  
3/12/2013Lewis C PellDirectorBuy45,000$1.10$49,500.00View SEC Filing  
3/7/2013Lewis C PellDirectorBuy60,000$1.09$65,400.00View SEC Filing  
3/4/2013Lewis C PellDirectorBuy20,000$1.06$21,200.00View SEC Filing  
2/26/2013Lewis C PellDirectorBuy66,266$1.01$66,928.66View SEC Filing  
2/21/2013Lewis C PellDirectorBuy25,000$0.99$24,750.00View SEC Filing  
2/19/2013Lewis C PellDirectorBuy5,000$0.99$4,950.00View SEC Filing  
2/7/2013Lewis C PellDirectorBuy9,000$0.99$8,910.00View SEC Filing  
2/5/2013Lewis C PellDirectorBuy25,000$1.01$25,250.00View SEC Filing  
2/1/2013Lewis C PellDirectorBuy10,000$1.09$10,900.00View SEC Filing  
12/27/2012Lewis C PellDirectorBuy10,000$1.07$10,700.00View SEC Filing  
12/17/2012Lewis C PellDirectorBuy21,600$1.10$23,760.00View SEC Filing  
12/13/2012Lewis C PellDirectorBuy18,961$1.10$20,857.10View SEC Filing  
12/10/2012Lewis C PellDirectorBuy6,656$1.10$7,321.60View SEC Filing  
12/3/2012Lewis C PellDirectorBuy8,360$1.10$9,196.00View SEC Filing  
11/30/2012Lewis C PellDirectorBuy45,748$1.10$50,322.80View SEC Filing  
11/27/2012Lewis C PellDirectorBuy3,593$1.10$3,952.30View SEC Filing  
11/23/2012Lewis C PellDirectorBuy39,357$1.09$42,899.13View SEC Filing  
11/19/2012Lewis C PellDirectorBuy57,050$1.08$61,614.00View SEC Filing  
11/14/2012Lewis C PellDirectorBuy100,000$1.15$115,000.00View SEC Filing  
11/12/2012Lewis C PellDirectorBuy24,852$1.17$29,076.84View SEC Filing  
9/6/2012Lewis C PellDirectorBuy10,000$1.37$13,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vision Sciences (NASDAQ CGNT) News Headlines

Source:
DateHeadline
 Vision Sciences Inc. (CGNT) Given $4.23 Consensus Price Target by Analysts Vision Sciences Inc. (CGNT) Given $4.23 Consensus Price Target by Analysts
www.americanbankingnews.com - April 20 at 9:22 PM
Financial Analysis: Zynex (ZYXI) versus Vision Sciences (CGNT)Financial Analysis: Zynex (ZYXI) versus Vision Sciences (CGNT)
www.americanbankingnews.com - April 13 at 5:09 AM
Financial Survey: NxStage (NXTM) and Vision Sciences (CGNT)Financial Survey: NxStage (NXTM) and Vision Sciences (CGNT)
www.americanbankingnews.com - April 12 at 9:20 AM
Vision Sciences (CGNT) Stock Rating Lowered by Zacks Investment ResearchVision Sciences (CGNT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:42 PM
The Law Offices of Vincent Wong Reminds Investors of an Investigation into Cogentix Medical, Inc. in Connection with the Sale of the Company to LABORIE Medical TechnologiesThe Law Offices of Vincent Wong Reminds Investors of an Investigation into Cogentix Medical, Inc. in Connection with the Sale of the Company to LABORIE Medical Technologies
finance.yahoo.com - April 9 at 4:38 PM
 Vision Sciences Inc. (CGNT) Given $4.23 Average Target Price by Analysts Vision Sciences Inc. (CGNT) Given $4.23 Average Target Price by Analysts
www.americanbankingnews.com - April 3 at 9:18 AM
Vision Sciences (CGNT) Stock Rating Upgraded by Zacks Investment ResearchVision Sciences (CGNT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 2 at 8:40 PM
Roth Capital Initiates Coverage on Vision Sciences (CGNT)Roth Capital Initiates Coverage on Vision Sciences (CGNT)
www.americanbankingnews.com - April 1 at 9:06 AM
Is It Time To Buy Cogentix Medical Inc (NASDAQ:CGNT)?Is It Time To Buy Cogentix Medical Inc (NASDAQ:CGNT)?
finance.yahoo.com - March 30 at 9:16 AM
Cogentix Medical (CGNT) Stock Rating Lowered by Roth CapitalCogentix Medical (CGNT) Stock Rating Lowered by Roth Capital
www.americanbankingnews.com - March 23 at 6:36 PM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cogentix Medical, Inc.- CGNTSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cogentix Medical, Inc.- CGNT
finance.yahoo.com - March 23 at 9:10 AM
Cogentix Medical (CGNT) to Release Quarterly Earnings on FridayCogentix Medical (CGNT) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - March 23 at 1:10 AM
The Law Offices of Vincent Wong Notifies Investors of an Investigation into Cogentix Medical, Inc. in Connection with the Sale of the Company to LABORIE Medical TechnologiesThe Law Offices of Vincent Wong Notifies Investors of an Investigation into Cogentix Medical, Inc. in Connection with the Sale of the Company to LABORIE Medical Technologies
finance.yahoo.com - March 21 at 10:15 AM
COGENTIX MEDICAL, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale to LABORIE Medical Technologies, Inc.COGENTIX MEDICAL, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale to LABORIE Medical Technologies, Inc.
finance.yahoo.com - March 19 at 4:35 PM
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Cogentix Medical, Inc. and Encourages Investors to Contact the Firm for Additional InformationSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Cogentix Medical, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - March 16 at 5:40 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Cogentix Medical, Inc. to LABORIE Medical Technologies is Fair to Shareholders – CGNTINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Cogentix Medical, Inc. to LABORIE Medical Technologies is Fair to Shareholders – CGNT
finance.yahoo.com - March 16 at 5:40 PM
WeissLaw LLP Investigates Cogentix Medical, Inc. AcquisitionWeissLaw LLP Investigates Cogentix Medical, Inc. Acquisition
finance.yahoo.com - March 15 at 5:11 PM
COGENTIX MEDICAL, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BuyoutCOGENTIX MEDICAL, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - March 14 at 6:02 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cogentix Medical, Inc. to LABORIE Medical Technologies is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cogentix Medical, Inc. to LABORIE Medical Technologies is Fair to Shareholders
finance.yahoo.com - March 14 at 6:02 PM
Cogentix Medical (CGNT) Downgraded by Aegis to HoldCogentix Medical (CGNT) Downgraded by Aegis to Hold
www.americanbankingnews.com - March 13 at 3:10 PM
Cogentix Medical (CGNT) to be Acquired by Laborie Medical Technologies for $3.85 Per Share in CashCogentix Medical (CGNT) to be Acquired by Laborie Medical Technologies for $3.85 Per Share in Cash
www.streetinsider.com - March 13 at 9:27 AM
Medical-device maker Cogentix to be sold in deal worth $239MMedical-device maker Cogentix to be sold in deal worth $239M
www.bizjournals.com - March 13 at 9:27 AM
Heres Why Cogentix Medical Inc. Stock Is Surging TodayHere's Why Cogentix Medical Inc. Stock Is Surging Today
finance.yahoo.com - March 13 at 9:27 AM
Cogentix Medical Inc to Host Earnings CallCogentix Medical Inc to Host Earnings Call
finance.yahoo.com - March 12 at 5:44 PM
Cogentix Medical Enters Definitive Merger Agreement to be Acquired by Laborie Medical Technologies for a Purchase Price of $3.85 Per Share in CashCogentix Medical Enters Definitive Merger Agreement to be Acquired by Laborie Medical Technologies for a Purchase Price of $3.85 Per Share in Cash
finance.yahoo.com - March 12 at 11:27 AM
Here's Why Cogentix Medical Inc. Stock Is Surging TodayHere's Why Cogentix Medical Inc. Stock Is Surging Today
finance.yahoo.com - March 12 at 11:27 AM
Broadfin Capital LLC Sells 333,540 Shares of Cogentix Medical Inc (CGNT)Broadfin Capital LLC Sells 333,540 Shares of Cogentix Medical Inc (CGNT)
www.americanbankingnews.com - March 3 at 4:55 AM
Cogentix Medical to Report Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018Cogentix Medical to Report Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018
finance.yahoo.com - March 1 at 8:58 AM
Cogentix Medical (CGNT) Set to Announce Earnings on WednesdayCogentix Medical (CGNT) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:24 AM
Comparing Cogentix Medical (CGNT) & Mazor Robotics (MZOR)Comparing Cogentix Medical (CGNT) & Mazor Robotics (MZOR)
www.americanbankingnews.com - February 13 at 10:54 AM
Cogentix Medical (CGNT) Upgraded to "Hold" at Zacks Investment ResearchCogentix Medical (CGNT) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 12 at 7:18 PM
Cogentix Medical Announces 17% Preliminary Fourth Quarter 2017 Year-Over-Year Revenue GrowthCogentix Medical Announces 17% Preliminary Fourth Quarter 2017 Year-Over-Year Revenue Growth
finance.yahoo.com - February 6 at 9:18 AM
Cogentix Medical (CGNT) Stock Rating Lowered by Zacks Investment ResearchCogentix Medical (CGNT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 1 at 7:14 PM
Zacks: Cogentix Medical, Inc. (CGNT) Given $4.58 Consensus Target Price by AnalystsZacks: Cogentix Medical, Inc. (CGNT) Given $4.58 Consensus Target Price by Analysts
www.americanbankingnews.com - January 17 at 11:40 AM
Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?
www.zacks.com - December 29 at 9:58 AM
ETFs with exposure to Cogentix Medical, Inc. : December 28, 2017ETFs with exposure to Cogentix Medical, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:02 PM
Head to Head Analysis: Cogentix Medical (CGNT) and Accuray (ARAY)Head to Head Analysis: Cogentix Medical (CGNT) and Accuray (ARAY)
www.americanbankingnews.com - December 28 at 3:44 PM
Cogentix Medical, Inc. :CGNT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Cogentix Medical, Inc. :CGNT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 2:24 PM
Cogentix Medical (CGNT) Downgraded by Zacks Investment Research to "Hold"Cogentix Medical (CGNT) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - December 20 at 5:56 PM
ETFs with exposure to Cogentix Medical, Inc. : December 13, 2017ETFs with exposure to Cogentix Medical, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 5:41 PM
Reviewing Cogentix Medical (CGNT) & Mindray Medical International (MR)Reviewing Cogentix Medical (CGNT) & Mindray Medical International (MR)
www.americanbankingnews.com - December 7 at 5:30 AM
Cogentix Medical Announces Palmetto GBA Extends Medicare Coverage on Urgent® PCCogentix Medical Announces Palmetto GBA Extends Medicare Coverage on Urgent® PC
finance.yahoo.com - December 6 at 9:26 AM
Cogentix Medical (CGNT) in Focus: Stock Moves 6.6% HigherCogentix Medical (CGNT) in Focus: Stock Moves 6.6% Higher
www.zacks.com - December 4 at 9:13 AM
Aegis Initiates Coverage on Cogentix Medical (CGNT)Aegis Initiates Coverage on Cogentix Medical (CGNT)
www.americanbankingnews.com - December 1 at 8:56 AM
Brokerages Anticipate Cogentix Medical, Inc. (CGNT) to Announce $0.00 EPSBrokerages Anticipate Cogentix Medical, Inc. (CGNT) to Announce $0.00 EPS
www.americanbankingnews.com - November 28 at 5:36 AM
Zacks: Cogentix Medical, Inc. (CGNT) Receives Average Recommendation of "Strong Buy" from AnalystsZacks: Cogentix Medical, Inc. (CGNT) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 21 at 5:23 PM
Cogentix Medical (CGNT) vs. Edwards Lifesciences Corporation (EW) Head to Head SurveyCogentix Medical (CGNT) vs. Edwards Lifesciences Corporation (EW) Head to Head Survey
www.americanbankingnews.com - November 19 at 11:36 AM
Cogentix Medical, Inc. (CGNT) Upgraded to "C" at TheStreetCogentix Medical, Inc. (CGNT) Upgraded to "C" at TheStreet
www.americanbankingnews.com - November 11 at 1:38 PM
Edited Transcript of CGNT earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of CGNT earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 8:51 PM
Why Cogentix Medical Inc (CGNT) Could Be A BuyWhy Cogentix Medical Inc (CGNT) Could Be A Buy
finance.yahoo.com - November 7 at 8:07 PM

SEC Filings

Vision Sciences (NASDAQ:CGNT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vision Sciences (NASDAQ:CGNT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vision Sciences (NASDAQ CGNT) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.